Nuvation Bio Inc   (NUVB)
Other Ticker:  
Price: $2.1200 $-0.11 -4.933%
Day's High: $2.28 Week Perf: 6.53 %
Day's Low: $ 2.08 30 Day Perf: 32.5 %
Volume (M): 1,010 52 Wk High: $ 2.34
Volume (M$): $ 2,141 52 Wk Avg: $1.58
Open: $2.25 52 Wk Low: $0.95

 Market Capitalization (Millions $) 463
 Shares Outstanding (Millions) 218
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -83
 Cash Flow (TTM) (Millions $) -114
 Capital Exp. (TTM) (Millions $) 0

Nuvation Bio Inc
Nuvation Bio Inc. is a biopharmaceutical company that specializes in the research, development, and delivery of innovative therapies for the treatment of chronic diseases. The company's mission is to improve the lives of patients by creating transformative medicines that address unmet medical needs.

Nuvation Bio's primary focus is on the development of a new class of drugs known as engineered decoy receptors. These drugs are designed to target the root cause of chronic diseases by neutralizing specific proteins in the body that contribute to disease progression. By doing so, the company hopes to provide patients with more effective and durable treatments that have fewer side effects than traditional drugs.

The company was founded in 2018 by several renowned scientists and biotech entrepreneurs, including Dr. George Gilliland and Dr. Robert Tjian. Dr. Gilliland is a leading expert in protein engineering and has led the development of several successful biotech companies, while Dr. Tjian is a renowned biochemist and former president of the Howard Hughes Medical Institute.

Since its inception, Nuvation Bio has made significant progress in the development of its platform technology and drug candidates. The company recently announced promising preclinical data for its lead program, NB-101, which targets a protein involved in the development of fibrotic diseases.

In addition to its internal drug development efforts, Nuvation Bio has established several partnerships and collaborations with other leading biopharmaceutical companies. These relationships provide the company with access to new technologies and expertise, which it can leverage to accelerate the development of its pipeline.

Overall, Nuvation Bio Inc. is an innovative biopharmaceutical company that is well-positioned to make a significant impact in the field of chronic disease treatment. The company's platform technology and pipeline of drug candidates hold great promise for improving the lives of millions of patients worldwide.

   Company Address: 1500 Broadway New York 10036 NY
   Company Phone Number: 208-6102   Stock Exchange / Ticker: NYSE NUVB
   NUVB is expected to report next financial results on March 14, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Business Update

Unveiling Nuvation Bio's Successful Progress in Oncology: Promising Financial Outcomes and Advancing Therapeutic Candidates

Published Thu, Feb 29 2024 9:01 PM UTC

The biopharmaceutical company, Nuvation Bio Inc., dedicated to addressing critical unmet needs in oncology, has recently reported its financial results for the fourth quarter and full year of 2023, along with a business update. This article aims to outline the significant facts presented in the report and assess their potential impact on the company's development and prospec...

Management Changes

Nuvation Bio Strengthens Leadership with Addition of Seasoned Biotech Veteran, Dr. Robert Mashal, to its Board of Directors

Published Mon, Jan 8 2024 9:10 PM UTC

Nuvation Bio Boosts Board of Directors with Addition of Dr. Robert Mashal
Nuvation Bio Inc., a leading biopharmaceutical company focused on addressing significant unmet needs in oncology with innovative therapeutic candidates, has announced the appointment of Dr. Robert Mashal to its Board of Directors. This exciting development comes as the company strives to further ad...

Product Service News

Illuminating Advanced Solid Tumor Treatment: NUV-1511 Cleared by FDA, a Beacon of Hope for Patients and Progress for Nuvation Bio

Published Mon, Jan 8 2024 9:05 PM UTC

Nuvation Bio Inc., a prominent biopharmaceutical company dedicated to addressing significant unmet needs in oncology, has made a significant stride in cancer treatment. The company recently announced that the U.S. Food and Drug Administration (FDA) has granted clearance for its investigational new drug (IND) application to evaluate NUV-1511, the first clinical candidate from...

Nuvation Bio Inc

NUVB's Financial Report Reveals Encouraging Results for Q3 2023 in Major Pharmaceutical Preparations Sector

In the Major Pharmaceutical Preparations industry, after the performance of large companies, attention is now shifting to the results of smaller companies. Nuvation Bio Inc. (NYSE: NUVB) recently reported its financial results for the third quarter of 2023, which indicates positive news for the company.
NUVB announced an operating loss of -$26.339 million for the third quarter of 2023, which is viewed as good news compared to the operating loss of -$29.338 million in the third quarter of 2022. This improvement in operating loss has generated optimism among most analysts about NUVB's potential. Additionally, the net loss for the company has also shown improvement, with diminishing returns compared to the same time frame a year ago. The shortfall for the third quarter of 2023 was -$19.649 million, while in the third quarter of 2022, it was -$27.203 million.

Business Update

Nuvation Bio's Strong Financials and Groundbreaking Research in Oncology Promise a Promising Future

Published Thu, Nov 2 2023 8:10 PM UTC

Nuvation Bio Inc., an innovative biopharmaceutical company, recently revealed its financial results for the third quarter of 2023 along with a comprehensive business update. With a strong focus on addressing critical unmet needs in the field of oncology, the company has been advancing its unique therapeutic candidates to tackle advanced solid tumors.
Nuvation Bio's ...



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com